These courses are intended for internal hospital staff.

Activity Description:

This case conference is designed for multidisciplinary head and neck cancer providers including medical oncologists and speech-language pathologists and will offer a blend of didactic, interactive experiences highlighting state-of-the-art head and neck cancer management. Renowned faculty members will demonstrate the most up-to-date information regarding head and neck cancer immunotherapy, and multidisciplinary management to optimize functional outcomes. Speech-language pathologists will learn novel diagnostic and therapeutic techniques to promote the highest functional outcomes.

Target Audience:

This course is designed for medical oncologists, surgeons, speech-language pathologists and other clinical experts relevant to both fields, including laboratory scientists, nurses, residents and social workers.

Learning Objectives:

1. Describe the clinical benefits of multidisciplinary head and neck cancer care
2. Interpret and assess the full array of diagnostic and therapeutic tools available to manage complex   voice and swallowing disorders
3. Discuss the advances in the areas of medical, surgical and radiation oncology in individuals with head and neck cancer
4. Examine novel approaches, targets, and therapies relevant to immunology in head and neck cancer
5. Summarize major changes in biomarker development in head and neck cancer

Moderator:

Andy Nemechek, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.